Keytruda 100mg

Keytruda 100mg Injection is an immunotherapy drug that contains the active ingredient pembrolizumab. It is utilized for the treatment of various cancers, including those affecting the skin, lungs, bladder, stomach, liver, gallbladder, cervix, kidney, colon, rectum, esophagus, breast, and uterus. Additionally, it is indicated for head and neck cancer as well as classical Hodgkin lymphoma, which is a type of blood cancer. Cancer is characterized by the uncontrolled and abnormal proliferation of cells. In some patients with advanced cancer, it can lead to lasting responses and enhanced survival rates. It has the potential to improve overall survival in individuals with multiple forms of advanced cancer. However, responses can vary among patients, and some may experience adverse effects.

Keytruda 100mg Injection is not advised for use in adolescents and children under the age of 18, with the exception of those aged three years and older who have classical Hodgkin lymphoma. It is important to use effective contraception during treatment and for at least four months following the final dose. As with any cancer therapy, the decision to administer this medication will be influenced by various factors, including the type and stage of cancer, the patient’s overall health status, and any other treatments the patient has undergone. Patients are encouraged to discuss the possible risks and benefits with their healthcare provider.